Dr. Patel on Benefit of Ipilimumab/Nivolumab Combo in High-Grade Neuroendocrine Carcinoma
April 3rd 2019
Sandip Patel, MD, associate professor of medicine at the University of California San Diego School of Medicine, discusses the benefit of the immune checkpoint inhibitor combination of ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with rare, high-grade neuroendocrine tumors.